

Anti-FGFR3 Antibody (Vofatamab Biosimilar)

Cat. No. AB333


Description	
Reactivities	Human
Target	FGFR3
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	52.0 kDa and 23.3 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
FGFR3 is tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts.	


Assay Data

Bis-Tris PAGE



Vofatamab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC




The purity of Vofatamab Biosimilar is greater than 95% as determined by SEC-HPLC.

Assay Data

ELISA Data

Vofatamab Biosimilar ELISA

0.1µg Human FGFR3 alpha (IIIb), His Tag Per Well



Immobilized Human FGFR3 alpha (IIIb), His Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Vofatamab Biosimilar with the EC50 of 5.3ng/ml determined by ELISA.